MetabolicHuman RCT
Retatrutide: what the trials show so far, and what is still a press release
Peer-reviewed trials show 24% weight loss at 48 weeks and large falls in liver fat; the headline 28% phase 3 figure is still company-reported.
Tirzepatide
A weekly GIP and GLP-1 receptor agonist, licensed for diabetes and weight management, with large randomised trials showing about 20% average weight loss.
- Also known as
- Mounjaro, Zepbound, LY3298176
- Area
- Metabolic
- Status
- Prescription medicine approved in the UK (Mounjaro) and US (Mounjaro, Zepbound)
Articles on Tirzepatide
MetabolicHuman RCT
Cagrilintide and CagriSema: what the amylin trials found
Alone, cagrilintide cut weight by about 11% in 26 weeks; paired with semaglutide it reached 20% at 68 weeks, but lost a head-to-head against tirzepatide.
MetabolicHuman RCT
SURMOUNT-1: how much weight tirzepatide took off in 72 weeks
At the top dose, people lost 20.9% of their body weight against 3.1% on placebo. Here is who was in the trial, what it cost them in side effects, and what it can’t tell you.
MetabolicHuman RCT
Tirzepatide: what SURMOUNT and SURPASS found
Around 20% average weight loss at 72 weeks, a head-to-head win over semaglutide, and heart-outcome data that matched rather than beat an older GLP-1 drug.